BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38132253)

  • 41. The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC.
    Yang Y; Shen X; Li R; Shen J; Zhang H; Yu L; Liu B; Wang L
    Oncotarget; 2017 Jul; 8(30):49773-49782. PubMed ID: 28572536
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR.
    Norton SE; Lechner JM; Williams T; Fernando MR
    Clin Biochem; 2013 Oct; 46(15):1561-5. PubMed ID: 23769817
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lessons learned from routine, targeted assessment of liquid biopsies for
    Mondaca S; Offin M; Borsu L; Myers M; Josyula S; Makhnin A; Shen R; Riely GJ; Rudin CM; Ladanyi M; Yu HA; Li BT; Arcila ME
    Acta Oncol; 2019 Nov; 58(11):1634-1639. PubMed ID: 31347936
    [No Abstract]   [Full Text] [Related]  

  • 44. Denaturation-Enhanced Droplet Digital PCR for Liquid Biopsies.
    Fitarelli-Kiehl M; Yu F; Ashtaputre R; Leong KW; Ladas I; Supplee J; Paweletz C; Mitra D; Schoenfeld JD; Parangi S; Makrigiorgos GM
    Clin Chem; 2018 Dec; 64(12):1762-1771. PubMed ID: 30274976
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
    Alegre E; Fusco JP; Restituto P; Salas-Benito D; Rodríguez-Ruiz ME; Andueza MP; Pajares MJ; Patiño-García A; Pio R; Lozano MD; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; Gonzalez A
    Tumour Biol; 2016 Oct; 37(10):13687-13694. PubMed ID: 27473086
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rapid detection of donor cell free DNA in lung transplant recipients with rejections using donor-recipient HLA mismatch.
    Zou J; Duffy B; Slade M; Young AL; Steward N; Hachem R; Mohanakumar T
    Hum Immunol; 2017 Apr; 78(4):342-349. PubMed ID: 28267558
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Synthetic DNA Construct to Evaluate the Recovery Efficiency of Cell-Free DNA Extraction and Bisulfite Modification.
    Goh SK; Cox DRA; Wong BKL; Musafer A; Witkowski T; Do H; Muralidharan V; Dobrovic A
    Clin Chem; 2021 Sep; 67(9):1201-1209. PubMed ID: 34151944
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Toward Personalised Liquid Biopsies for Urothelial Carcinoma: Characterisation of ddPCR and Urinary cfDNA for the Detection of the
    Russo IJ; Ju Y; Gordon NS; Zeegers MP; Cheng KK; James ND; Bryan RT; Ward DG
    Bladder Cancer; 2018 Jan; 4(1):41-48. PubMed ID: 29430506
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel method for liquid-phase extraction of cell-free DNA for detection of circulating tumor DNA.
    Janku F; Huang HJ; Pereira DY; Kobayashi M; Chiu CH; Call SG; Woodbury KT; Chao F; Marshak DR; Chiu RYT
    Sci Rep; 2021 Oct; 11(1):19653. PubMed ID: 34608196
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases.
    Huang R; Xu X; Li D; Chen K; Zhan Q; Ge M; Zhou X; Liang X; Guan M
    Target Oncol; 2019 Jun; 14(3):343-350. PubMed ID: 31161597
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A nanowire-based liquid biopsy method using cerebrospinal fluid cell-free DNA for targeted management of leptomeningeal carcinomatosis.
    Choi W; Cho Y; Park SY; Hwang KH; Han JY; Lee Y
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):213-222. PubMed ID: 32705364
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction.
    Janku F; Huang HJ; Fujii T; Shelton DN; Madwani K; Fu S; Tsimberidou AM; Piha-Paul SA; Wheler JJ; Zinner RG; Naing A; Hong DS; Karp DD; Cabrilo G; Kopetz ES; Subbiah V; Luthra R; Kee BK; Eng C; Morris VK; Karlin-Neumann GA; Meric-Bernstam F
    Ann Oncol; 2017 Mar; 28(3):642-650. PubMed ID: 27993791
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
    Wang W; Song Z; Zhang Y
    Cancer Med; 2017 Jan; 6(1):154-162. PubMed ID: 28000387
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of Circulating Cell-Free DNA Extraction Methods for Downstream Analysis in Cancer Patients.
    Leest PV; Boonstra PA; Elst AT; Kempen LCV; Tibbesma M; Koopmans J; Miedema A; Tamminga M; Groen HJM; Reyners AKL; Schuuring E
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32414097
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Using circulating cell-free DNA to monitor personalized cancer therapy.
    Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
    Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dynamic cfDNA Analysis by NGS in
    Ma L; Li H; Wang D; Hu Y; Yu M; Zhang Q; Qin N; Zhang X; Li X; Zhang H; Wu Y; Lv J; Yang X; Yu R; Zhang S; Wang J
    Front Oncol; 2021; 11():643199. PubMed ID: 33842353
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of the JAK2 V617F Mutation in Urinary Cell-free DNA in Patients with Myeloproliferative Neoplasms.
    Hosoi H; Hori Y; Fukutsuka K; Osuga M; Koh Y; Mushino T; Hanaoka N; Yamamoto N; Ohno H; Sonoki T
    Intern Med; 2023 Nov; ():. PubMed ID: 38008450
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Circulating cell-free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre-analytical biases.
    Soscia R; Della Starza I; De Novi LA; Ilari C; Ansuinelli M; Cavalli M; Bellomarino V; Cafforio L; Di Trani M; Cazzaniga G; Fazio G; Santoro A; Salemi D; Spinelli O; Tosi M; Terragna C; Robustelli V; Bellissimo T; Colafigli G; Breccia M; Chiaretti S; Di Rocco A; Martelli M; Guarini A; Del Giudice I; Foà R
    Hematol Oncol; 2023 Feb; 41(1):50-60. PubMed ID: 36251440
    [TBL] [Abstract][Full Text] [Related]  

  • 59. EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial.
    Fassunke J; Ihle MA; Lenze D; Lehmann A; Hummel M; Vollbrecht C; Penzel R; Volckmar AL; Stenzinger A; Endris V; Jung A; Lehmann U; Zeugner S; Baretton G; Kreipe H; Schirmacher P; Kirchner T; Dietel M; Büttner R; Merkelbach-Bruse S
    Virchows Arch; 2017 Oct; 471(4):509-520. PubMed ID: 28884371
    [TBL] [Abstract][Full Text] [Related]  

  • 60. EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors.
    Li C; Jia R; Liu H; Zhang B; Wang C
    Diagn Pathol; 2018 Aug; 13(1):49. PubMed ID: 30103780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.